tbuckley/cabot-search huggingface dataset:
Clinical and biological characteristics of non-small cell lung cancer (NSCLC) harbouring EGFR mutation: Results of the nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)
Authors: C. Leduc, H. Blons, B. Besse, J.-P. Merlio, D. Debieuvre, A. Lemoine, I. Monnet, D. Pouessel, P.P. Bringuier, M. Poudenx, I. Rouquette, F. Vaylet, F. Morin, A. Langlais, E. Quoix, G. Zalcman, D. Moro-Sibilot, J. Cadranel, M. Beau-Faller, F. Barlesi
Journal: Annals of Oncology (2016)
HOXC8 regulates self-renewal, differentiation and transformation of breast cancer stem cells
Authors: Mansi Shah, Ryan Cardenas, Belinda Wang, Jenny Persson, Nigel P. Mongan, Anna Grabowska, Cinzia Allegrucci
Journal: Molecular Cancer (2017)

Homeobox genes are master regulators of cell fate during embryonic development and their expression is altered in cancer. By regulating the balance between cell proliferation and differentiation, they maintain homeostasis of normal tissues. Here, we screened the expression of homeobox genes in mammary stem cells to establish their role in stem cells transformation in breast cancer. Using a Homeobox Genes PCR array, we screened 83 homeobox genes in normal cancer breast stem/progenitor cells isolated by flow cytometry. The candidate gene HOXC8 epigenetic regulation was studied by DNA methylation and miRNA expression analyses. Self-renewal and differentiation of HOXC8-overexpressing or knockdown cells were assessed by flow cytometry and mammosphere, 3D matrigel and soft agar assays. Clinical relevance of in vitro findings were validated by bioinformatics analysis of patient datasets from TCGA and METABRIC studies. In this study we demonstrate altered expression of homeobox genes in breast cancer stem/progenitor cells. HOXC8 was consistently downregulated in stem/progenitor cells of all breast molecular subtypes, thus representing an interesting tumour suppressor candidate. We show that downregulated expression of HOXC8 is associated with DNA methylation at the gene promoter and expression of miR196 family members. Functional studies demonstrated that HOXC8 gain of function induces a decrease in the CD44+/CD24-/low cancer stem cell population and proportion of chemoresistant cells, with a concomitant increase in CD24+ differentiated cells. Increased HOXC8 levels also decrease the ability of cancer cells to form mammospheres and to grow in anchorage-independent conditions. Furthermore, loss of HOXC8 in non-tumorigenic mammary epithelial cells expands the cancer stem/progenitor cells pool, increases stem cell self-renewal, prevents differentiation induced by retinoic acid and induces a transformed phenotype. Taken together, our study points to an important role of homeobox genes in breast cancer stem/progenitor cell function and establishes HOXC8 as a suppressor of stemness and transformation in the mammary gland lineage.
OS4.3 Diagnostic performance of static 18F-fluoroethyl-L-tyrosine positron emission tomography parameters to differentiate recurrent brain tumours from non-neoplastic treatment-related changes: a meta-analysis
Authors: B. Muoio, G. Treglia, M. Reinert, A. Richetti, L. Giovanella, G. A. Pesce
Journal: Neuro-Oncology (2016)

AbstractAim:to assess the pooled diagnostic accuracy of static 18F-fluoroethyl-L-tyrosine positron emission tomography (18F-FET-PET) parameters [maximal and mean lesion-to-background ratios (LBRmax and LBRmean)] in discriminating recurrent/progressive brain tumours (BTs) from non-neoplastic treatment-related changes.Methods:A comprehensive literature search of published studies on the role of 18F-FET-PET in this setting was performed (from inception up to February 2016) using Pubmed, Scopus and Google Scholar databases. Pooled sensitivity, specificity and diagnostic odd ratio (DOR) of static 18F-FET-PET parameters on a per lesion-based analysis were assessed. The area under the summary receiver-operating-characteristic curve (AUC) was calculated. Sub-analyses were performed whether significant heterogeneity was found (I2>50%). Pooled weighted mean difference (WMD) of static 18F-FET-PET parameters among malignant and benign lesions was calculated. Pooled ROC analysis to assess the best LBRmax and LBRmean cut-off values to discriminate malignant and benign lesions was performed.Results:Ten articles including 422 patients with BTs were selected. Pooled sensitivity, specificity, DOR and AUC of static 18F-FET-PET parameters in discriminating recurrent/progressive BTs from non-neoplastic treatment-related changes were 84% (95%CI:80–88%), 80% (95%CI:71–88%), 34 (95%CI:15–77) and 0.92, respectively, for LBRmax, and 81% (95%CI:76–86%), 86% (95%CI:76–93%), 30 (95%CI:13–73) and 0.92, respectively, for LBRmean. As significant heterogeneity between the selected studies was found (I2>50%), a sub-analysis including only patients with high-grade gliomas (HGG) was performed (for LBRmax only). This sub-analysis showed that pooled sensitivity, specificity, DOR and AUC of static 18F-FET-PET in discriminating recurrent/progressive HGG from non-neoplastic treatment-related changes were 95% (95%CI:90–98%), 83% (95%CI:68–93%), 44 (95%CI:13–148) and 0.95, respectively, without significant heterogeneity (I2<50%). Pooled WMD among recurrent/progressive BTs and treatment-related changes were 0.93 (95%CI:0.6–1.3; p<0.0001) for LBRmax and 0.59 (95%CI:0.3–0.8; p<0.0001) for LBRmean. LBRmax and LBRmean values of 2.2 and 2, respectively, were the best cut-off values to discriminate recurrent/progressive BTs from non-neoplastic treatment-related changes at pooled ROC analysis.Conclusions:Evidence-based data show that static 18F-FET-PET parameters are accurate in differentiating recurrent/progressive BTs and nonneoplastic treatment-related changes, in particular in patients with HGG. Large prospective multicenter trials and cost-effectiveness analyses are needed to substantiate the role of 18F-FET-PET in this setting.
Combination of FXI Antisense Oligonucleotide and Plavix® Treatment Results in Enhanced Antithrombotic Activity without Increased Risk of Bleeding in Mouse Models of Thrombosis.
Authors: Dacao Gao, Jeff Crosby, Robert MacLeod, Gourab Bhattacharjee, Ester C Lowenberg, Marcel Levi, Brett P. Monia
Journal: Blood (2009)
Gene Mutations and Treatment Outcome in the Context of Chlorambucil (Clb) without or with the Addition of Rituximab (R) or Obinutuzumab (GA-101, G) - Results of an Extensive Analysis of the Phase III Study CLL11 of the German CLL Study Group
Authors: Sven Estenfelder, Eugen Tausch, Sandra Robrecht, Jasmin Bahlo, Valentin Goede, Matthias Ritgen, Jacques JM van Dongen, Anton W. Langerak, Günter Fingerle-Rowson, Michael Kneba, Kirsten Fischer, Michael Hallek, Hartmut Döhner, Stephan Stilgenbauer
Journal: Blood (2016)
TMIC-10. AN IL-1β/IL-1R PRO-TUMORIGENIC SIGNALING LOOP IN GLIOBLASTOMA
Authors: Milota Kaluzova, David Gutmann, Dolores Hambardzumyan
Journal: Neuro-Oncology (2016)

Glioblastoma (GBM) is the most aggressive and lethal malignant primary brain tumor in adults, with a high degree of intratumoral heterogeneity at both the cellular and molecular levels. The Cancer Genome Atlas (TCGA) project divided GBM into the proneural (PN), neural, classical, and mesenchymal (MES) subtypes based on distinct gene expression patterns. A further layer of complexity in GBM emerges from the tumor microenvironment in which these tumor cells develop and grow. The GBM microenvironment is composed of a wide variety of non-neoplastic stromal cells, including the vasculature, various infiltrating and resident immune cells, and other glial cell types. The most abundant non-neoplastic cell population in the GBM microenvironment is tumor-associated macrophages (TAMs). Of all the subtypes, PN-GBM is the most resistant to anti-neoplastic cell-specific targeted therapies, and high expression of TAM-related genes correlates with worse survival in PN patients only. In contrast, the MES-GBM subtype expresses the highest levels of TAM-enriched genes, and these tumors harbor higher numbers of TAMs compared to PN-GBM. To examine TAM-GBM interactions, we used a genetically-engineered mouse model of PN-GBM, and showed that tumor cells induce the expression of the key pro-inflammatory cytokine IL-1β in TAMs. This TAM-derived IL-1β activates IL-1β/IL-1R1 signaling in PN-GBM tumor cells, leading to increased stemness and growth, as well as increased expression of all four genes of the monocyte chemoattractant protein (MCP) network, which attracts TAMs to GBM via chemotaxis in PN-GBM cells. Finally, by generating PN-GBM tumors in IL-1β knockout (KO) and wild-type (WT) mice, we have shown dramatic decreases in gliomagenesis and significantly prolonged survival of GBM-bearing mice in an IL-1β KO background. Collectively, these findings reveal that IL-1β is a master regulator of MCP network expression and an important driver of tumor growth and TAM recruitment in PNGBM.
PURE01: An open label, single-arm, phase 2 study of the anti-programmed death (PD)-1 monoclonal antibody (moAb) pembrolizumab for neoadjuvant therapy of muscle-invasive urothelial bladder carcinoma (miUBC)
Authors: A. Necchi, L. Mariani, A. Anichini, P. Giannatempo, D. Raggi, E. Togliardi, G. Calareso, N. Di Genova, F. Crippa, R. Salvioni
Journal: Annals of Oncology (2016)
Emerging role of liquid biopsy in detection of EGFR mutations from metastatic Lung Adenocarcinomas (mLA): concordance between analysis on tissue samples and in circulating free tumor DNA (cftDNA)
Authors: A. Veccia, O. Caffo, S. Girlando, S. Fasanella, M. Dipasquale, M. Bertolin, S. Kinspergher, M. Barbareschi, E. Galligioni
Journal: Annals of Oncology (2016)
Immunosuppression and Experimental Lymphoma: Reply
Authors: Lance E. Perryman
Journal: JNCI Journal of the National Cancer Institute (1973)

Journal Article Immunosuppression and Experimental Lymphoma: Reply Get access Lance E. Perryman, D.V.M. Lance E. Perryman, D.V.M. Department of Veterinary Pathology Washington State University, Pullman, Washington Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 50, Issue 5, May 1973, Pages 1412–1413, https://doi.org/10.1093/jnci/50.5.1412-b Published: 01 May 1973
A multicenter study of the impact of body mass index (BMI) on the incidence of pathologic complete response (pCR) among Saudi patients with locally advanced breast cancer (LABC) post neoadjuvant chemotherapy (NCth)
Authors: A.M. Abdelwarith, K. Alsaleh, N. Abdelaziz, A. Ali, S. Elsamany, A. Rasmy, O. Elfarargy, S. Husain, A. Rikabi
Journal: Annals of Oncology (2016)
Reply
Authors: Thierry Gustot, Javier Fernandez, Elisabet Garcia, Marco Pavesi, Vicente Arroyo
Journal: Hepatology (2017)

Potential conflict of interest: Nothing to report. Reply: We thank Cardoso et al. for their comments about our paper.1 The concept of futility of care is always a complex and controversial issue. Thanks to the collection of objective data, we are moving from an era in which intensivists were reluctant to admit patients with cirrhosis to an intensive care unit (ICU) to one in which clinicians have access to robust criteria that help them to decide to maintain or withdraw/withhold organ support in patients who have cirrhosis and multiple organ failure (OF). Because of the limitation of resources, we need to address the issue of futility of care by collecting externally validated prospective data. Like others, Cardoso et al. challenge our suggested criteria for futility of care.2 In their single‐center experience of 50 patients with acute‐on‐chronic liver failure (ACLF), patients with four or more OFs or a Chronic Liver Failure Consortium ACLF score (CLIF‐C ACLFs) > 64 at 3‐7 days after ICU admission had 90‐day transplant‐free survival rates of 9% and 14%, respectively, in contrast to 0% in our observation. Several factors could explain this discrepancy. In our multicenter European CANONIC study, analysis was performed in patients with ACLF grade 3 (ACLF‐3) at enrollment or at any time of the 28‐day follow‐up, in contrast to the data presented by Cardoso et al., where all ACLF patients (46% with ACLF‐3) admitted to an ICU were assessed. On diagnosis of ACLF‐3, there was also no critical cutoff number of OFs or level of CLIF‐C ACLFs over which the mortality rate reached 100% but, at day 3‐7, patients with four or more OFs (n = 25) or CLIF‐C ACLF score > 64 (n = 24) had a 90‐day mortality of 100%. Moreover, ICU admission of ACLF patients included in the CANONIC study was not systematic (10% in patients with ACLF‐1, 32% in ACLF‐2 and 67% in ACLF‐3) in comparison with the Cardoso et al. study, where all patients were managed in an ICU at baseline. Finally, type of OF and organ support at day 3‐7 could also differ between both series. In CANONIC, 11 out of the 25 patients with four or more organ failures (44%) were under mechanical ventilation, renal replacement therapy, and vasopressors at day 3‐7 and 10 (40%) under vasopressors and mechanical ventilation or renal replacement therapy (n = 5, each). In conclusion, we believe that it is essential to collect high‐quality prospective externally validated data to try to define inappropriate, ineffective, or futile treatment in critical ill patients with cirrhosis. Our study presents—for the first time—potential criteria for defining futility of care in patients with ACLF. Obviously, these criteria must be always questioned with improvement of care and the introduction of new therapeutic strategies.
A Prospective Study of Young Chronic Lymphocytic Leukemia (CLL) Patients Investigated at Diagnosis: Distribution and Clinical Significance of Prognostic Factors
Authors: Ilaria Del Giudice, Francesca Romana Mauro, Maria Stefania De Propris, Simona Santangelo, Marilisa Marinelli, Nadia Peragine, Valeria Di Maio, Mauro Nanni, Francesca Mancini, Daniele Armiento, Luisa Quattrocchi, Francesca Paoloni, Anna Guarini, Robert Foa
Journal: Blood (2008)
Treatment Outcome of Steroid-Refractory Chronic Graft-Versus-Host Disease with Weekly Rituximab Followed by Maintenance Rituximab: a KSBMT Multicenter Phase II Study.
Authors: Seok Jin Kim, Chang Ki Min, Jong Wook Lee, Bin Cho, Chul Won Jung, Ho Jin Shin, Hawk Kim, Joo-Sep Jung, Won Sik Lee, Deok-Hwan Yang, Young Don Joo, Hyoung Jin Kang, Sung-Soo Yoon, Hoon Kook, Sang Kyun Sohn, Yoo Hong Min, Hee-Sook Park, Hack Ki Kim, Hyo Seop Ahn, Jong Ho Won
Journal: Blood (2009)
Rituximab Subcutaneous Formulation (SC-R) Is Safe, Effective and Cost-Saving in Patients Suffering from Autoimmune Hemolytic Anemia (AIHA)
Authors: Francesco Iuliano, Eleonora Iuliano, Alessia Perricelli, Angelo Pomillo, Maria Luci, Maria Aquila Santoro, Pierosandro Tagliaferri, Pierfrancesco Tassone
Journal: Blood (2016)
P13.12 Long term survival of patients treated by Gamma Knife radiosurgery with a total of 5 to 21 brain metastases.
Authors: D. Devriendt, C. Renier, N. Massager
Journal: Neuro-Oncology (2016)

CONCLUSION: In this study we validated both the M-GPA and Chowdhury OS score.The Chowdhury OS score proved to be the most accurate score to categorize patients with MBM in risk groups with corresponding statistically significant median overall survival time.Contrary to Chowdhury et al the follow-up time in our study was sufficient for the low-risk group to reach the median overall survival time which was 13 months.P13.
Array-Based Comparative Genomic Hybridization (Array-CGH) in Multiple Myeloma (MM) and Plasma Cell Leukemia (PCL): Recurrent Imbalances within a Highly Heterogeneous Background of Genomic Disruption.
Authors: Daniela Drandi, Marco Ladetto, Sonia Vallet, Loredana Santo, Irene Ricca, Maria Dell’Aquila, Luigia Monitillo, Monica Astolfi, Marina Ruggeri, Maria Teresa Ambrosini, Federica De Marco, Lydia Marino, Barbara Mantoan, Gloria Pagliano, Paola Omedè, Antonio Palumbo, Mario Boccadoro.
Journal: Blood (2005)
Analysis of HOXA5 and HOXB3 Expression Complements Conventional Cytogenetic Analysis in Acute Myeloid Leukemia.
Authors: Damian P.J. Finnegan, Vivien M. Hodges, Alexander Thompson, Michael F. Quinn, Mervyn Humphries, Terence R.J. Lappin, Mary Frances McMullin, Graham R. Ball
Journal: Blood (2007)
Child vs Adult Onset of Attention-Deficit/Hyperactivity Disorder
Authors: Mary V. Solanto
Journal: JAMA Psychiatry (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
LBA-06 IMAB362: a novel immunotherapeutic antibody targeting the tight-junction protein component CLAUDIN18.2 in gastric cancer
Authors: S.E. Al-Batran, M. Schuler, Z. Zvirbule, G. Manikhas, F. Lordick, O. Tureci, C. Huber
Journal: Annals of Oncology (2016)
Clinical practice and evidence on rehabilitation for patients undergoing hematopoietic cell transplantation
Authors: Junichiro Inoue, Daisuke Makiura, Miyuki Kashiwa, Rei Ono, Atsuo Okamura, Kimikazu Yakushijin, Ryuichi Saura, Yoshitada Sakai
Journal: Annals of Oncology (2016)
Characterizing Canine Lymphoma As a Potential Large Animal Model of Human Diffuse Large B-Cell Lymphoma
Authors: Kristy L. Richards, Alison Motsinger-Reif, Hsiao-Wei Chen, Yuri D. Fedoriw, Cheng Fan, Dahlia M. Nielsen, Rachael Thomas, Chris Smith, Sandeep S. Dave, Charles M. Perou, Matthew Breen, Steven E. Suter
Journal: Blood (2011)
Proposal of improved prognostic index for patients with extranodal natural killer/T cell lymphoma treated with non-anthracycline based treatment
Authors: Y. Kang, S. Seo, J.Y. Hong, D.H. Yoon, S. Kim, J.S. Park, J. Huh, S.-W. Lee, J.-S. Ryu, C. Suh
Journal: Annals of Oncology (2016)
The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortality
Authors: Joshua A. Hill, Bryan T. Mayer, Hu Xie, Wendy M. Leisenring, Meei-Li Huang, Terry Stevens-Ayers, Filippo Milano, Colleen Delaney, Mohamed L. Sorror, Brenda M. Sandmaier, Garrett Nichols, Danielle M. Zerr, Keith R. Jerome, Joshua T. Schiffer, Michael Boeckh
Journal: Blood (2017)
RARE-50. SPINDLE CELL AND EPITHELIOID TUMOR OF UNKNOWN ORIGIN IN A PREGNANT FEMALE: A NOVEL CASE PRESENTATION AND LITERATURE REVIEW
Authors: Mansour Mathkour, Juanita Garces
Journal: Neuro-Oncology (2016)

The tectal region of the brain describes an anatomically complex area containing a number of telencephalic, diencephalic, and vascular structures. As such, the area is home to a variety of different cell types. In this report we describe a case of an aggressive epithelioid neoplasm of unknown origin in a pregnant female. A 22-year-old female at 27 weeks gestation presented with progressive headache, nausea, and vomiting and bilateral horizontal nystagmus with restricted lateral eye movements. MRI of the head revealed a mass-like lesion in the left ambient cistern with associated mass effect and resultant obstructive hydrocephalus. There was multifocal leptomeningeal enhancement involving the surface of both the cerebral and cerebellar hemispheres as well as the quadrigeminal plate and entire spine. CSF sent for analysis was nondiagnostic. The patient underwent a suboccipital craniotomy for biopsy and a ventriculoperitoneal shunt was placed. Histopathology displayed an unusual neoplasm consisting of spindle and epithelioid cells with inconclusive features and an ambiguous origin. The cytology and features were reminiscent of meningiothelial cells with low atypia staining strongly for S-100 and weakly for the EMA and progesterone markers characteristic of meningioma, but also that the tumor was behaving in an aggressive manner. The patient and her family have decided on palliative care measures rather than further interventional treatment In the world of modern medicine, genomics, and histochemistry, the ability to categorize even the most esoteric of tumors is rapidly advancing. Still, there occasionally exists the potential for neoplasms of unknown origins, particularly in histologically variable regions.
IMST-22. THERAPEUTIC TARGETING OF THE Wnt-β-CATENIN PATHWAY ALLEVIATES GLIOMA-INDUCED IMMUNOSUPPRESSION AND CAUSES INHIBITION OF GLIOMA PROGRESSION
Authors: Suhnrita Chaudhuri, Jason Miska
Journal: Neuro-Oncology (2016)

Glioblastoma multiforme (GBM) is the most common malignant neoplasm of astrocytic lineage. Despite aggressive treatment, GBM patients have a median survival of 12-15 months. The Wnt-β-catenin pathway has garnered attention in GBM research as it mediates stemness, proliferation and therapeutic resistance in human GBMs. Therapeutic targeting of this pathway could thus serve as an effective therapeutic option for GBM. The Wnt-β-catenin pathway attenuates T-cell activation and enhances survival of regulatory T cells. However, despite extensive studies on the role of this pathway in GBM progression, the significance of this pathway in glioma-induced immunosuppression has never been investigated. Here we hypothesize that targeting the Wnt-β-catenin pathway not only halts glioma progression but also causes alleviation of immunosuppression in GBMs. Immunofluorescence staining showed that in GL261/C57BL6 murine glioma model, huge overexpression of Wnt3a occurs in tumor compared to normal brain. Western blot revealed Wnt3a overexpression in both lysates of adherent GL261 cells as well as GL261 neurospheres. Treatment of GL261 cells with the inhibitor of porcupine, an O-acyl transferase necessary for Wnt secretion, results in decreased Wnt3a secretion and decreased cytoplasmic β-catenin levels, suggesting that the pathway is inhibited in GL261 cells upon treatment with the inhibitor. Graded dosing of GL261 cells with porcupine inhibitor showed cell viability dropping to 50% on 10µM treatment. Flowcytometric studies on T-cells isolated form murine spleen and draining lymph nodes showed significant increases (P<0.001) of both percentage of Tregs (from 4.05 ± 0.36% to 28.36 ± 2.67%) and their proliferation (from 27.73 ± 6.8% to 67.08 ± 3.49%) upon Wnt3a treatment whereas effector CD4 cells were decreased (P<0.001). Through the current study we suggest that overabundance of Wnt in glioma may be an additional means for glioma-induced T-cell immunosuppression and therefore propose a novel angle whereby therapeutic targeting of the Wnt-β-catenin pathway in GBM will alleviate glioma-mediated immunosuppression and inhibit glioma progression.
Safety and Efficacy of Posaconazole for the Treatment of Invasive Fungal Infections After Failure of One Prior Line of Therapy
Authors: Shariq Haider, Laverdiere Michel, Maryse M. Power, Coleman Rotstein, Shahid Husain, Jeffrey H. Lipton, Karen Doucette, Peter Phillips, Andre Galarneau, Jean-Francois Pouliot
Journal: Blood (2011)